Clinical Trials
Ascelia Pharma presents study showing comparable efficacy of Orviglance lesion visualization and detection to Gadolinium
Ascelia Pharma AB is presenting a study in which Orviglance® (manganese chloride tetrahydrate, former working name Mangoral) was compared against a gadolinium-based contrast agent at one of the world’s largest radiology conference, RSNA, in Chicago, Illinois.
Orviglance is a novel...
Clinical Trials
Single Dose of Regen-Cov Provides Long-Term Protection Against COVID-19
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1
During the 8-month assessment period there were 0 hospitalizations...
Clinical Trials
Ferrer announces first patient enrollment of FNP122 in ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis treatment
Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has announced the next major milestone in its mission to develop transformative therapies for Amyotrophic Lateral Sclerosis (ALS) – marked by the first...
Clinical Trials
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration
Antios Therapeutics, Inc. and Assembly Biosciences, Inc. announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing...
Clinical Trials
Moleculin obtains UK MHRA authorisation for Phase Ia trial of Covid-19 drug
Moleculin Biotech has obtained the UK Medicines and Healthcare Products Regulatory Agency (MHRA) authorisation to initiate a Phase Ia clinical trial of its drug, WP1122, in the country to treat Covid-19.
An inhibitor of metabolism/glycosylation, WP1122 is a prodrug of...
Clinical Trials
Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus Future Clinical Development in Sepsis/septic shock
Modus Therapeutics Holding AB , a company developing innovative treatments for patients with high unmet medical needs, announces that Symbiosis Pharmaceutical Services Ltd (“Symbiosis”), a specialist contract manufacturing organization (CMO), has started manufacturing sevuparin drug product securing the supply...
Clinical Trials
Brii Bio Initiates Submission of EUA Filing to U.S. FDA for BRII-196/BRII-198, , its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients
Brii Biosciences Limited a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, announced the filing of an emergency use authorization (EUA) application for its investigational SARS-CoV-2 (virus that causes COVID-19)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read